⁍ Pfizer said Lyrica sales fell 33% to $352 million.
⁍ Total sales fell to $12.13 billion from $12.68 billion a year ago.
– Pfizer reported a 4.3% drop in third-quarter sales, hurt by increased competition for its off-patent pain drug Lyrica and lower demand for some of its treatments during the COVID-19 pandemic. In the third quarter, Pfizer said Lyrica sales fell 33% to $352 million. Total sales fell to $12.13 billion from $12.68 billion a year ago. As the COVID-19 pandemic crimps demand for certain Pfizer therapies and damages global economies, investors are keenly focused on seeing late-stage study data of the vaccine candididate being developed by Pfizer and German partner BioNTech SE 22UAy.F, reports Reuters.
Source: https://www.reuters.com/article/us-pfizer-results/pfizer-third-quarter-sales-fall-on-lower-demand-for-pain-drugs-idUSKBN27C1GT